{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269548","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.557860+00:00","generated_at":"2026-05-16T23:56:35.107276+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MindMed Q3 cash $209M, raises $242.8M; MM120 Phase 3 GAD/MDD readouts on track for 2026","bullets":["Cash, cash equivalents and investments of $209.1M at Sept 30, 2025; net proceeds of $242.8M from Oct 31 offering extend runway into 2028.","R&D expenses $31.0M in Q3 2025 vs $17.2M in Q3 2024, driven by MM120 program costs.","Phase 3 Voyage (GAD) topline data expected 1H 2026; Panorama (GAD) 2H 2026.","Phase 3 Emerge (MDD) topline data accelerated to mid-2026 (from 2H 2026); Ascend (MDD) to initiate mid-2026.","Phase 2a of MM402 for ASD to start Q4 2025; MM120 Phase 2b published in JAMA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269548","json":"https://secwatch.observer/filing/0001193125-25-269548.json","markdown":"https://secwatch.observer/filing/0001193125-25-269548.md","text":"https://secwatch.observer/filing/0001193125-25-269548.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525269548/0001193125-25-269548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525269548/mnmd-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:56:35.107276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}